Management of parkinson's disease dementia: Practical considerations

Drugs and Aging

Volumn 23, Issue 10, 2006, Pages 807-822

  Rongve, Arvid ^a,b,d   Aarsland, Dag ^b,c  

^a HAUGESUND HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d Psychiatric Clinic   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; LEVODOPA; NEUROLEPTIC AGENT; RIVASTIGMINE; TACRINE;

BRAIN ATROPHY; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; DEMENTIA; DIFFERENTIAL DIAGNOSIS; HIPPOCAMPUS; HUMAN; NAUSEA; NEUROCHEMISTRY; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIDOTOMY; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SLEEP DISORDER; SYMPTOMATOLOGY; THALAMOTOMY; TREMOR; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 33750509422     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623100-00004     Document Type: Review

References (140)

1. Parkinson J. An essay on the shaking palsy. London: Whittingham & Rowland, 1817
2. The ICD-10 classification of mental and behaviour disorders: diagnostic criteria for research. Geneva: World Heath Organization, 1993
3. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: US: American Psychiatric Association, 1994
4. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005 Dec 27; 65 (12): 1863-72
5. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000; 54 (5): 1050-8
6. Foltynie T, Brayne CE, Robbins TW, et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK: the CamPaIGN study. Brain 2004; 127 (Pt 3): 550-60
7. Janvin CC, Larsen JP, Aarsland D, et al. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006 May 23; 21 (9): 1343-9
8. de Rijk MC, Breteler MM, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 1995; 45 (12): 2143-6
9. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005; 20 (10): 1255-63
10. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60 (3): 387-92
11. Hely MA, Morris JG, Reid WG, et al. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20 (2): 190-9
12. Aarsland D, Andersen K, Larsen JP, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001; 56 (6): 730-6
13. Yip AG, Brayne C, Matthews FE. Risk factors for incident dementia in England and Wales: the Medical Research Council Cognitive Function and Ageing Study. A population-based nested case-control study. Age Ageing 2006 Mar; 35 (2): 154-60
14. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2 (4): 229-37
15. Rosenberg RN, Green JB, White CL, et al. Dominantly inherited dementia and parkinsonism, with non-Alzheimer amyloid plaques: a new neurogenetic disorder. Ann Neurol 1989; 25 (2): 152-8
16. Marder K, Flood P, Cote L, et al. A pilot study of risk factors for dementia in Parkinson's disease. Mov Disord 1990; 5 (2): 156-61
17. Golbe LI, Di Iorio G, Bonavita V, et al. A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 1990; 27 (3): 276-82
18. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003; 302 (5646): 841
19. Inzelberg R, Chapman J, Treves TA, et al. Apolipoprotein E4 in Parkinson disease and dementia: new data and meta-analysis of published studies. Alzheimer Dis Assoc Disord 1998; 12 (1): 45-8
20. Beyer MK, Aarsland D, Greve OJ, et al. Visual rating of white matter hyperintensities in Parkinson's disease. Mov Disord 2006 Feb; 21 (2): 223-9
21. Haugarvoll K, Aarsland D, Wentzel-Larsen T, et al. The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. Acta Neurol Scand 2005; 112 (6): 386-90
22. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17 (3): 137-45
23. Janvin CC, Larsen JP, Salmon DP, et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov Disord 2006 Mar; 21 (3): 337-42
24. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005; 18 (3): 149-54
25. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 2002; 17 (6): 1221-6
26. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44 (12): 2308-14
27. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999; 67 (4): 492-6
28. Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand 2005; 112 (3): 201-7
29. Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with PD and dementia: frequency, profile and associated caregiver stress. J Neurol Neurosurg Psychiatry. Epub 2006 Jul 4
30. Aarsland D, Larsen JP, Karlsen K, et al. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int J Geriatr Psychiatry 1999; 14 (10): 866-74
31. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43 (11): 2227-9
32. Diederich NJ, Valliant M, Leischen M, et al. Sleep apnea syndrome in Parkinson's disease: a case-control study in 49 patients. Mov Disord 2005; 20 (11): 1413-8
33. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005; 9 (3): 185-200
34. Ferman TJ, Boeve BF, Smith GE, et al. Dementia with Lewy bodies may present as dementia and REM sleep behavior disorder without parkinsonism or hallucinations. J Int Neuropsychol Soc 2002 Nov; 8 (7): 907-14
35. Boeve BF, Silber MH, Ferman TJ. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17 (3): 146-57
36. Boeve BF, Silber MH, Ferman TJ, et al. REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology, 1998; 51 (2): 363-70
37. Ringman JM, Simmons JH. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000; 55 (6): 870-1
38. Baumann C, Ferini-Strambi L, Waldvogel D, et al. Parkinsonism with excessive daytime sleepiness: a narcolepsy-like disorder? J Neurol 2005; 252 (2): 139-45
39. Braak H, Ghebremedhin E, Rub U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318 (1): 121-34
40. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59 (4): 591-6
41. Del Tredici K, Rub U, De Vos RA, et al. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002; 61 (5): 413-26
42. Jellinger KA, Seppi K, Wenning GK, et al. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002; 109 (3): 329-39
43. Apaydin H, Ahlskog JE, Parisi JE, et al. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002; 59 (1): 102-12
44. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000; 54 (10): 1916-21
45. Mattila PM, Rinne JO, Helenius H, et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000; 100 (3): 285-90
46. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82 (4): 239-59
47. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997 Jul-Aug; 18 (4 Suppl.): S1-2
48. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group [published erratum appears in Neurobiol Aging 1998 May-Jun; 19 (3): 285]. Neurobiol Aging 1998 Mar-Apr; 19 (2): 109-16
49. Aarsland D, Perry R, Brown A, et al. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005; 58 (5): 773-6
50. Aarsland D, Perry E, Perry R, et al. The neuropathology of dementia in Parkinson disease: a prospective community based study. First World Parkinson Congress; 2006 Feb 22-26; Washington, DC
51. Tsuboi Y, Dickson DW. Dementia with Lewy bodies and Parkinson's disease with dementia: are they different? Parkinsonism Relat Disord 2005; 11 Suppl. 1: S47-51
52. Jellinger KA. Pathological substrate of dementia in Parkinson's disease: its relation to DLB and DLBD. Parkinsonism Relat Disord 2006 Mar; 12 (2): 119-20
53. Rinne JO, Portin R, Ruottinen H, et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 2000; 57 (4): 470-5
54. Lewis SJ, Dove A, Robbins TW, et al. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003; 23 (15): 6351-6
55. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002; 51 (2): 156-64
56. Lange KW, Paul GM, Naumann M, et al. Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J Neural Transm Suppl 1995; 46: 423-32
57. Cash R, Dennis T, L'Heureux R, et al. Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology 1987; 37 (1): 42-6
58. Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983; 275 (2): 321-8
59. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60 (12): 1745-8
60. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and Parkinsonian dementia. J Neurol 2006 Feb; 253 (2): 242-7
61. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65 (11): 1716-22
62. Ramirez-Ruiz B, Marti MJ, Tolosa E, et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J Neurol 2005; 252 (11): 1345-52
63. Summerfield C, Junque C, Tolosa E, et al. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study. Arch Neurol 2005; 62 (2): 281-5
64. Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 1996; 46 (3): 678-81
65. Camicioli R, Moore MM, Kinney A, et al. Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003; 18 (7): 784-90
66. Burton EJ, McKeith IG, Burn DJ, et al. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127 (Pt 4): 791-800
67. Burton EJ, McKeith IG, Burn DJ, et al. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005; 20 (12): 1571-6
68. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004; 62 (2): 181-7
69. Walker MP, Ayre GA, Cummings JL, et al. The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale: two methods to assess fluctuating confusion in dementia. Br J Psychiatry 2000; 177: 252-6
70. Folstein M, Folstein SE, McHugh PR. A practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98
71. Cahn-Weiner DA, Williams K, Grace J, et al. Discrimination of dementia with Lewy bodies from Alzheimer disease and Parkinson disease using the clock drawing test. Cogn Behav Neurol 2003; 16 (2): 85-92
72. Mattis S. Dementia rating scale. In: Bellak L, Karasu TB, editors. Geriatric psychiatry: a handbook for psychiatrists and primary care physicians. New York: Grune & Stratton, 1976: 108-121
73. Athey RJ, Porter RW, Walker RW. Cognitive assessment of a representative community population with Parkinson's disease (PD) using the Cambridge Cognitive Assessment-Revised (CAMCOG-R). Age Ageing 2005; 34 (3): 268-73
74. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 1999; 28 (1): 39-43
75. Suzuki M, Kurita A, Hashimoto M, et al. Impaired myocardial (123)I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 2006 Jan 15; 240 (1-2): 15-9
76. Firbank MJ, Burn DJ, McKeith IG, et al. Longitudinal study of cerebral blood flow SPECT in Parkinson's disease with dementia, and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20 (8): 776-82
77. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006; 66 (1): 41-8
78. Scarmeas N, Hadjigeorgiou GM, Papadimitriou A, et al. Motor signs during the course of Alzheimer disease. Neurology 2004; 63 (6): 975-82
79. Scarmeas N, Albert M, Brandt J, et al. Motor signs predict poor outcomes in Alzheimer disease. Neurology 2005; 64 (10): 1696-703
80. Kraybill ML, Larson EB, Tsuang DW, et al. Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64 (12): 2069-73
81. Cohen-Mansfield J, Mintzer JE. Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord 2005; 19 (1): 37-40
82. Brodaty H, Draper BM, Millar J, et al. Randomized controlled trial of different models of care for nursing home residents with dementia complicated by depression or psychosis. J Clin Psychiatry 2003; 64 (1): 63-72
83. Teri L, Logsdon RG, Uomoto J, et al. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci 1997; 52 (4): 159-66
84. Teri L, Logsdon RG, McCurry SM. Nonpharmacologic treatment of behavioral disturbance in dementia. Med Clin North Am 2002; 86 (3): 641-56, viii
85. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004; 17 (3): 164-71
86. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351 (24): 2509-18
87. Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006 Apr; 21 (4): 456-61
88. Wesnes KA, McKeith I, Edgar C, et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 2005; 65 (10): 1654-6
89. Ballard CG, Aardsland D, McKeith I, et al. Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 2002; 59 (11): 1714-20
90. de Maindreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson's disease: a follow-up study. Mov Disord 2005; 20 (2): 212-7
91. Thomas AJ, Burn DJ, Rowan EN, et al. A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20 (10): 938-44
92. Reddy S, Factor SA, Molho ES, et al. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17 (4): 676-81
93. Fernandez HH, Treischmann ME, Burke MA, et al. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord 2003; 18 (5): 510-4
94. Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20 (8): 958-63
95. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340 (10): 757-63
96. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999; 353 (9169): 2041-2
97. Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000; 12 (3): 364-9
98. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005 Sep; 20 (9): 1161-9
99. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14 (6): 540-5
100. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73 (6): 629-35
101. Marinus J, Visser M, Martinez-Martin P, et al. A short psychosocial questionnaire for patients with Parkinson's disease: the SCOPA-PS. J Clin Epidemiol 2003 Jan; 56 (1): 61-7
102. Marinus J, Visser M, van Hilten JJ, et al. Assessment of sleep and sleepiness in Parkinson disease. Sleep 2003 Dec 15; 26 (8): 1049-54
103. Comella CL, Nardine TM, Diederich NJ, et al. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998; 51 (2): 526-9
104. Wolters EC, Berendse HW, Stam CJ. Mental dysfunction in Parkinson's disease III. 1st ed. Amsterdam: VU University Press, 2006
105. Lemke MR, Brecht HM, Koester J, et al. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005; 17 (2): 214-20
106. Lemke MR, Brecht HM, Koester J, et al. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci, Epub 2006 Jun 28
107. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10 (4): 399-406
108. Burn D, Emre M, McKeith I, et al. Response to rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. 7th International Conference of Alzheimer's disease and Parkinson's disease; 2005 Mar 9-13; Sorrento
109. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006; (1): CD004747
110. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000; 16 (5): 365-79
111. Kulisevsky J, Garcia-Sanchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 2000 Jul; 15 (4): 613-26
112. Kulisevsky J, Avila A, Barbanoj M, et al. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996; 119 (Pt 6): 2121-32
113. Perry EK, Kilford L, Lees AJ, et al. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003; 54 (2): 235-8
114. Ballard CG, Perry RH, McKeith IG, et al. Neuroleptics are associated with more severe tangle pathology in dementia with Lewy bodies. Int J Geriatr Psychiatry 2005; 20 (9): 872-5
115. Rektorova I, Rektor I, Bares M, et al. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 2005; 12 (1): 9-15
116. Voon V, Kubu C, Krack P, et al. Deep brain stimulation: neuropsychological and neuropsychiatric issues. Mov Disord 2006; 21 Suppl. 14: S305-27
117. Smeding HM, Speelman JD, Koning-Haanstra M, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 2006; 66 (12): 1830-6
118. Schupbach M, Gargiulo M, Welter ML, et al. Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology 2006; 66 (12): 1811-6
119. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001 Mar 8; 344 (10): 710-9
120. Lagrange E, Krack P, Moro E, et al. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology 2002 Dec 24; 59 (12): 1976-8
121. Berney A, Vingerhoets F, Perrin A, et al. Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology 2002 Nov 12; 59 (9): 1427-9
122. Burn DJ, Troster AI. Neuropsychiatric complications of medical and surgical therapies for Parkinson's disease. J Geriatr Psychiatry Neurol 2004; 17 (3): 172-80
123. Castelli L, Perozzo P, Genesia ML, et al. Sexual well being in parkinsonian patients after deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry 2004; 75 (9): 1260-4
124. Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 2005; 65 (3): 481-2
125. Sabbagh MN, Hake AM, Ahmed S, et al. The use of memantine in dementia with Lewy bodies. J Alzheimer's Dis 2005; 7 (4): 285-9
126. Menendez-Gonzalez M, Calatayud MT, Blazquez-Menes B. Exacerbation of Lewy bodies dementia due to memantine. J Alzheimers Dis 2005; 8 (3): 289-91
127. Lokk J. Memantine can relieve certain symptoms in Parkinson disease: improvement achieved in two out of three described cases with dyskinesia and cognitive failure [in Swedish]. Lakartidningen, 2004; 101 (23): 2003-6
128. Inzelberg R, Bonuccelli U, Schechman E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 2006 May 16; 21 (9): 1375-9
129. Wolters EC. Dopaminomimetic psychosis in Parkinson's disease patients: diagnosis and treatment. Neurology 1999; 52 (7 Suppl. 3): S10-3
130. Wolters EC, Berendse HW. Management of psychosis in Parkinson's disease. Curr Opin Neurol 2001; 14 (4): 499-504
131. Factor SA, Molho ES, Brown DL. Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology 1998; 50 (5): 1456-8
132. Singer C, Papapetropoulos S, Gonzalez MA, et al. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Mov Disord 2005; 20 (7): 873-7
133. Aarsland D, Perry R, Larsen JP, et al. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. J Clin Psychiatry 2005; 66 (5): 633-7
134. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14 (3): 191-210
135. Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005; 330 (7489): 445
136. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand 1986 Mar; 73 (3): 295-7
137. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5 (3): 225-9
138. Fernandez HH, Trieschmann ME, Friedman JH. Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 2003; 26 (9): 643-59
139. Gomez-Esteban JC, Zarranz JJ, Velasco F, et al. Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005; 28 (3): 111-4
140. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004; 27 (1): 4-5